In today’s fast-paced world, threats can evolve quickly and without warning. As the pharmaceutical industry has operations and supply chains spanning the globe, companies are vulnerable to ...

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue grew 10.5%, while EBITDA surged 15.3% with improved margins. The company ...

On the net interest income (NII) front, analysts remain divided and see the growth between -7.6 per cent and 9 per cent Y-o-Y.

The individual AUM of investors in B-30 surged 27 per cent in FY25, reaching ₹10.8 trn. In comparison, AUM in the top 30 cities (T-30) increased by 21 per cent to ₹30.5 trn during the same period ...